The MAGE-encoded antigens that are recognized by cytolytic T lymphocytes (CTL) are shared by many tumors and are strictly tumor specific. Clinical trials involving therapeutic vaccination of cancer patients with MAGE antigenic peptides or proteins are in progress. To increase the range of patients e
A MAGE-1 peptide recognized on HLA-DR15 by CD4+ T cells
✍ Scribed by Pascal Chaux; Bernard Lethé; Jacques Van Snick; Jurgen Corthals; Erwin S. Schultz; César L. Cambiaso; Thierry Boon; Pierre van der Bruggen
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 106 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0014-2980
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract NY‐ESO‐1 is one of the most immunogenic cancer antigens eliciting strong humoral and cellular immune responses in patients with NY‐ESO‐1‐expressing malignancies. Since CD4+ T cells play a critical role in generating and maintaining antigen‐specific cellular and humoral immune responses,
## Abstract Treatment of chondrosarcomas is limited to resection because these tumors are unresponsive to standard adjuvant treatments, such as chemotherapy and radiation. We have previously shown that high‐grade chondrosarcomas express unspecified members of the Melanoma Antigen (MAGE) gene family
## Abstract CD4^+^ Th cells that are restricted by MHC class II molecules play an important role in the induction of antitumor immune responses. We have established a stable CD4^+^ Th cell clone (Th35‐1A) from the PBMCs of a patient with primary cutaneous melanoma. The Th cell clone is noncytolytic